D-BIOMARK (NCT03691311), an ongoing early phase 1 study, will measure neoadjuvant denosumab antiproliferative and pro-apoptotic activity and correlate it with RANKL and RANK tumor expression, BCa phenotype, and patient’s menopausal status. This evidence concerns the gene TNFSF11 and neoplasm.